470 related articles for article (PubMed ID: 30739035)
1. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
2. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
3. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
4. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
5. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
Adamson Barnes NS; Mitchell VA; Kazantzis NP; Vaughan CW
Br J Pharmacol; 2016 Jan; 173(1):77-87. PubMed ID: 26398331
[TBL] [Abstract][Full Text] [Related]
6. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
Anderson WB; Gould MJ; Torres RD; Mitchell VA; Vaughan CW
Neuropharmacology; 2014 Jun; 81():224-30. PubMed ID: 24384256
[TBL] [Abstract][Full Text] [Related]
7. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Jayamanne A; Greenwood R; Mitchell VA; Aslan S; Piomelli D; Vaughan CW
Br J Pharmacol; 2006 Feb; 147(3):281-8. PubMed ID: 16331291
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
[TBL] [Abstract][Full Text] [Related]
9. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
Sasso O; Bertorelli R; Bandiera T; Scarpelli R; Colombano G; Armirotti A; Moreno-Sanz G; Reggiani A; Piomelli D
Pharmacol Res; 2012 May; 65(5):553-63. PubMed ID: 22420940
[TBL] [Abstract][Full Text] [Related]
10. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Starowicz K; Makuch W; Korostynski M; Malek N; Slezak M; Zychowska M; Petrosino S; De Petrocellis L; Cristino L; Przewlocka B; Di Marzo V
PLoS One; 2013; 8(4):e60040. PubMed ID: 23573230
[TBL] [Abstract][Full Text] [Related]
11. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
13. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
14. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD.
Fidelman S; Mizrachi Zer-Aviv T; Lange R; Hillard CJ; Akirav I
Eur Neuropsychopharmacol; 2018 May; 28(5):630-642. PubMed ID: 29519609
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
18. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety.
Danandeh A; Vozella V; Lim J; Oveisi F; Ramirez GL; Mears D; Wynn G; Piomelli D
Psychopharmacology (Berl); 2018 Nov; 235(11):3211-3221. PubMed ID: 30251159
[TBL] [Abstract][Full Text] [Related]
19. Blockade of alcohol escalation and "relapse" drinking by pharmacological FAAH inhibition in male and female C57BL/6J mice.
Zhou Y; Schwartz BI; Giza J; Gross SS; Lee FS; Kreek MJ
Psychopharmacology (Berl); 2017 Oct; 234(19):2955-2970. PubMed ID: 28730283
[TBL] [Abstract][Full Text] [Related]
20. ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.
Lee WH; Carey LM; Li LL; Xu Z; Lai YY; Courtney MJ; Hohmann AG
Mol Pain; 2018; 14():1744806918801224. PubMed ID: 30157705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
